Health data company Truveta said Monday it’s partnering with health systems and drugmakers to launch the Truveta Genome Project, a database of genetic data that is expected to accelerate personalized medicine and help discover new drugs.
Truveta plans to use leftover biospecimens from patients — after they consent — receiving routine health care at participating health systems to create the database. The genetic data, cross-referenced with the patients’ de-identified medical records, will be available for purchase for researchers and life sciences companies.
Pharmaceutical company Regeneron has invested $119.5 million in Truveta’s project, and its laboratory subsidiary the Regeneron Genetics Center will sequence the exomes of the first 10 million volunteers for the program. DNA sequencer manufacturer Illumina has also invested $20 million in the project, which also builds on a 2021 investment and partnership from Microsoft, who will provide the cloud infrastructure for the project.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
